The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, ...

In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...

In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than ...

Multidrug resistance in cancer can be overcome by combining a drug that blocks a key enzyme with another anticancer drug, ...

A discovery of how to target mutated proteins in tumors made a decade ago never matured into a surefire way of destroying ...

This recognition follows another recent honor for Mr. Kras, who was named a finalist for the Entrepreneur Of The Year® 2024 New Jersey Award by Ernst & Young (EY US). This award celebrates innovative ...

As chief executive officer, chairman and one of the founders of Belvidere-based hydroponic farming company Edible Garden, Kras is focused on driving the sustainable agriculture market with cutting ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its role in guiding targeted treatments.

The Company anticipates sharing initial results from the study in March 2025. These results will inform Silexion's development strategy for SIL-204.